Woodline Partners LP Has $13.80 Million Position in Annexon, Inc. (NASDAQ:ANNX)

Woodline Partners LP lowered its holdings in Annexon, Inc. (NASDAQ:ANNX - Free Report) by 21.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,690,787 shares of the company's stock after selling 739,373 shares during the period. Woodline Partners LP owned approximately 2.52% of Annexon worth $13,804,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. TFG Asset Management GP Ltd lifted its holdings in shares of Annexon by 78.5% in the fourth quarter. TFG Asset Management GP Ltd now owns 1,400,000 shares of the company's stock valued at $7,182,000 after purchasing an additional 615,645 shares in the last quarter. Shay Capital LLC purchased a new stake in shares of Annexon in the fourth quarter valued at $159,000. Sphera Funds Management LTD. purchased a new stake in shares of Annexon in the fourth quarter valued at $6,377,000. Rafferty Asset Management LLC lifted its holdings in shares of Annexon by 23.5% in the fourth quarter. Rafferty Asset Management LLC now owns 218,369 shares of the company's stock valued at $1,120,000 after purchasing an additional 41,544 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Annexon by 5.6% in the fourth quarter. Point72 Asset Management L.P. now owns 5,626,796 shares of the company's stock valued at $28,865,000 after purchasing an additional 299,798 shares in the last quarter.

Annexon Trading Down 2.6%

Annexon stock traded down $0.06 during mid-day trading on Tuesday, hitting $2.06. 199,501 shares of the company's stock were exchanged, compared to its average volume of 1,783,608. The stock has a market cap of $225.46 million, a P/E ratio of -1.96 and a beta of 1.24. Annexon, Inc. has a 1-year low of $1.29 and a 1-year high of $7.85. The stock has a 50 day moving average of $1.85 and a two-hundred day moving average of $3.41.

Annexon (NASDAQ:ANNX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.07). As a group, research analysts predict that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ANNX has been the topic of a number of research reports. HC Wainwright dropped their price target on shares of Annexon from $20.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Needham & Company LLC dropped their price target on shares of Annexon from $16.00 to $11.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.